Response to rituximab-based therapy and risk factor analysis in epstein barr virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: A study from the infectious diseases working party of the european group for blood and marrow transplantation

Clinical Infectious Diseases

Volumn 57, Issue 6, 2013, Pages 794-802

  Styczynski, Jan ^a   Gil, Lidia ^b   Tridello, Gloria ^c   Ljungman, Per ^d,e   Donnelly, J Peter ^f   Van Der Velden, Walter ^f   Omar, Hamdy ^d   Martino, Rodrigo ^g   Halkes, Constantijn ^h   Faraci, Maura ⁱ   Theunissen, Koen ^j   Kalwak, Krzysztof ^k   Hubacek, Petr ^l   Sica, Simona ^m   Nozzoli, Chiara ⁿ   Fagioli, Franca ^o   Matthes, Susanne ^p   Diaz, Miguel A ^q   Migliavacca, Maddalena ^r   Balduzzi, Adriana ^r   Tomaszewska, Agnieszka ^s   Camara, Rafael De La ^t   Van Biezen, Anja ^h   Hoek, Jennifer ^h   Iacobelli, Simona ^u   Einsele, Hermann ^v   Cesaro, Simone ^c,w   more..

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^c Policlinico GB Rossi   (Italy)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e KAROLINSKA INSTITUTE   (Sweden)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^g HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^h LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ G GASLINI INSTITUTE   (Italy)

^j UNIVERSITY OF LEUVEN   (Belgium)

^k WROCLAW MEDICAL UNIVERSITY   (Poland)

^l UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^m CATHOLIC UNIVERSITY   (Italy)

ⁿ CAREGGI UNIVERSITY HOSPITAL   (Italy)

^o Onco Ematologia Pediatrica   (Italy)

^p ST ANNA CHILDREN S HOSPITAL   (Austria)

^q HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

^r UNIVERSITY OF MILANO BICOCCA   (Italy)

^s INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

^t HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^u UNIVERSITY OF ROME TOR VERGATA   (Italy)

^v UNIVERSITY OF WÜRZBURG   (Germany)

^w Clinica di Oncoematologia Pediatrica   (Italy)

more..

Author keywords

Epstein Barr virus; hematopoietic stem cell transplantation; post transplant lymphoproliferative disorder; prognostic model; risk factors

Indexed keywords

ANTINEOPLASTIC AGENT; CIDOFOVIR; IMMUNOSUPPRESSIVE AGENT; RITUXIMAB; VIRUS DNA;

ADULT; AGE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHILD; DONOR LYMPHOCYTE INFUSION; DRUG DOSE REDUCTION; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; EXTRANODAL DISEASE; FAMILY; FAMILY DONOR; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MORTALITY; ORGAN DONOR; OVERALL SURVIVAL; POST TREATMENT SURVIVAL; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; PROGNOSIS; REMISSION; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT RESPONSE; UNRELATED DONORS; VIRUS LOAD;

EPSTEIN-BARR VIRUS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER; PROGNOSTIC MODEL; RISK FACTORS;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CHILD; CHILD, PRESCHOOL; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; EUROPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOLOGIC FACTORS; INFANT; KAPLAN-MEIER ESTIMATE; LYMPHOPROLIFERATIVE DISORDERS; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; VIRAL LOAD;

EID: 84883243154     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit391     Document Type: Article

References (34)

1. Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 1999; 94:2208-16.
2. Styczynski J, Reusser P, Einsele H, et al. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant 2009; 43:757-70.
3. McGuirk JP, Seropian S, Howe G, Smith B, Stoddart L, Cooper DL. Use of rituximab and irradiated donor-derived lymphocytes to control Epstein-Barr virus-associated lymphoproliferation in patients undergoing related haplo-identical stem cell transplantation. Bone Marrow Transplant 1999; 24:1253-8.
4. Doubrovina E, Oflaz-Sozmen B, Prockop SE, et al. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood 2012; 119:2644-56.
5. Heslop HE, Slobod KS, Pule MA, et al. Long-term outcome of EBVspecific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010; 115:925-35.
6. De Pasquale MD, Mastronuzzi A, De Vito R, et al. Unmanipulated donor lymphocytes for EBV-related PTLD after T-cell depleted HLAhaploidentical transplantation. Pediatrics 2012; 129:e189-94.
7. Barker JN, Doubrovina E, Sauter C, et al. Successful treatment of EBVassociated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes. Blood 2010; 116:5045-9.
8. Faye A, Quartier P, Reguerre Y, et al. Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. Br J Haematol 2001; 115:112-8.
9. Styczynski J, Einsele H, Gil L, Ljungman P. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Transpl Infect Dis 2009; 11:383-92.
10. Cesaro S, Pegoraro A, Tridello G, et al. A prospective study on modulation of immunosuppression for Epstein-Barr virus reactivation in pediatric patients who underwent unrelated hematopoietic stem-cell transplantation. Transplantation 2010; 89:1533-40.
11. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25:579-86.
12. Kaplan EL, Meier P. Non parametric estimation for incomplete observations. J Am Stat Assoc 1958; 53:457-81.
13. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Assoc 1972; 135:185-98.
14. Gray R. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16:1141-54.
15. Cox DR. Regression model and life tables. J R Stat Soc Ser B 1972; 34:187-220.
16. Hubacek P, Cinek O, Kulich M, et al. EBV quantification in children after allogeneic hematopoietic stem cell transplantation [article in Czech]. Cas Lek Cesk 2006; 145:301-6.
17. Reddiconto G, Chiusolo P, Fiorini A, et al. Assessment of cellular origin and EBV status in a PTLD after double cord blood transplantation. Leukemia 2007; 21:2552-4.
18. Chiusolo P, Metafuni E, Cattani P, et al. Prospective evaluation of Epstein-Barr virus reactivation after stem cell transplantation: association with monoclonal gammopathy. J Clin Immunol 2010; 30: 894-902.
19. Faraci M, Lanino E, Micalizzi C, et al. Unrelated hematopoietic stem cell transplantation for Cernunnos-XLF deficiency. Pediatr Transplant 2009; 13:785-9.
20. Faraci M, Caviglia I, Morreale G, et al. Viral-load and B-lymphocyte monitoring of EBV reactivation after allogeneic hemopoietic SCT in children. Bone Marrow Transplant 2010; 45:1052-5.
21. Orazi A, Hromas RA, Neiman RS, et al. Posttransplantation lymphoproliferative disorders in bone marrow transplant recipients are aggressive diseases with a high incidence of adverse histologic and immunobiologic features. Am J Clin Pathol 1997; 107:419-29.
22. Ghobrial IM, Habermann TM, Maurer MJ, et al. Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders. J Clin Oncol 2005; 23: 7574-82.
23. Leblond V, Dhedin N, Mamzer Bruneel MF, et al. Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J Clin Oncol 2001; 19:772-8.
24. Ghobrial IM, Habermann TM, Ristow KM, et al. Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era. Leuk Lymphoma 2005; 46:191-6.
25. Smith JM, Corey L, Healey PJ, Davis CL, McDonald RA. Adolescents are more likely to develop posttransplant lymphoproliferative disorder after primary Epstein-Barr virus infection than younger renal transplant recipients. Transplantation 2007; 83:1423-8.
26. Evens AM, David KA, Helenowski I, et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol 2010; 28:1038-46.
27. Stevens SJ, Verschuuren EA, Pronk I, et al. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood 2001; 97:1165-71.
28. Sundin M, Le Blanc K, Ringden O, et al. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation. Haematologica 2006; 91:1059-67.
29. Landgren O, Gilbert ES, Rizzo JD, et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 2009; 113:4992-5001.
30. Larouche JF, Berger F, Chassagne-Clement C, et al. Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome. J Clin Oncol 2010; 28:2094-100.
31. Diepstra A, van Imhoff GW, Schaapveld M, et al. Latent Epstein-Barr virus infection of tumor cells in classical Hodgkin's lymphoma predicts adverse outcome in older adult patients. J Clin Oncol 2009; 27: 3815-21.
32. Cesaro S, Murrone A, Mengoli C, et al. The real-time polymerase chain reaction-guided modulation of immunosuppression enables the preemptive management of Epstein-Barr virus reactivation after allogeneic haematopoietic stem cell transplantation. Br J Haematol 2005; 128: 224-33.
33. Christopeit M, Schutte V, Theurich S, Weber T, Grothe W, Behre G. Rituximab reduces the incidence of acute graft-versus-host disease. Blood 2009; 113:3130-1.
34. Cutler C, Miklos D, Kim HT, et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 2006; 108:756-62.